A highly diverse team imagining the undiscovered

RENAL RESEARCH INSTITUTE

A highly diverse
team imagining
the undiscovered

ABOUT THE RENAL RESEARCH INSTITUTE

The heart of RRI’s capacity for innovation is our ability to examine complex problems through multiple lenses.

The Renal Research Institute (RRI) is an internationally recognized incubator of ideas, treatment processes, and technologies to improve the lives of kidney patients. RRI’s leadership in computational biomedicine and data analytics, as well as our access to a large patient population, accelerates the pace of scientific discoveries and their translation into applied medicine. Our team includes some of the brightest minds from around the world, who, along with their disciplinary expertise, bring a deep understanding of global healthcare issues and challenges.

Our Research

RRI’s pioneering leadership in computational biomedicine and data analytics drives breakthroughs, including the introduction of virtual clinical trials and smartphone-based diagnostics. Not only does our interdisciplinary approach foster wide-ranging research within the global framework of Fresenius Medical Care, it encourages collaboration with academic institutions in the United States, Asia, Europe, Latin America, and Africa.

Latest Research & News

Latest Research

  • Marcus Dariva, Murilo Guedes, Vladimir Rigodon, Peter Kotanko, John W Larkin, Bruno Ferlin, Roberto Pecoits-Filho, Pasqual Barretti, Thyago Proença de Moraes

    RESULTSWe analysed data of 848 patients (814 starting on CAPD and 34 starting on APD). The SBP decreased by 4 (SD 22) mmHg when transitioning from CAPD to APD (p < 0.001) and increased by 4 (SD 21) mmHg when transitioning from APD to CAPD (p = 0.38); consistent findings were seen for DBP. There was no significant change in the number of antihypertensive drugs prescribed before and after transition.CONCLUSIONSTransition between PD modalities seems to directly impact on BP levels. Further studies are needed to confirm if switching to APD could be an effective treatment for uncontrolled hypertension among CAPD patients.BACKGROUNDHypertension is a leading cause of kidney failure, affects most dialysis patients and associates with adverse outcomes. Hypertension can be difficult to control with dialysis modalities having differential effects on sodium and water removal. There are two main types of peritoneal dialysis (PD), automated peritoneal dialysis (APD) and continuous ambulatory peritoneal dialysis (CAPD). It is unknown whether one is superior to the other in controlling blood pressure (BP). Therefore, the aim of our study was to analyse the impact of switching between these two PD modalities on BP levels in a nationally representative cohort.METHODSThis was a cohort study of patients on PD from 122 dialysis centres in Brazil (BRAZPD II study). Clinical and laboratory data were collected monthly throughout the study duration. We selected all patients who remained on PD at least 6 months and 3 months on each modality at minimum. We compared the changes in mean systolic/diastolic blood pressures (SBP/DBP) before and after modality transition using a multilevel mixed-model where patients were at first level and their clinics at the second level.

No Results Found

Latest News

  • Renal Research Institute’s 23rd International Conference on Dialysis - Advances in Kidney Disease is rescheduled for April 20-23, 2021, but acknowledges the renal community has immediate access to the latest COVID-19 kidney care science and knowledge via online platforms. New York, March 18, 2021 – While the Renal Research Institute (RRI) has rescheduled its 23rd...

No Results Found

Education

LATEST EPISODE

Solutes, Scaling, Sex: are we getting the dosing of dialysis, right?

Apr 27, 2022

Join Dr. Peter Kotanko, MD, FASN, Head of Biomedical Evidence Generation and Renal Research Institute, and John Daugirdas, MD, FACP, FASN, Clinical Professor of Medicine at the University of Illinois School of Medicine at Chicago, as they discuss aspects around dialysis patient prescription.